As the line between pharma and biotech gets blurrier, Bayer has agreed to outsource some of its preclinical testing to CuraGen. In the smaller part of a two-pronged, billion-dollar-plus deal, Bayer committed $39 million over five years for CuraGen’s pharmacogenomic and toxicogenomic technologies and invested $85 million in its stock.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.